Now showing items 1-2 of 2
Should the patent system for new medicines be abolished?
(Clin Pharmacol Ther, 2007-11)
Economic return of clinical trials performed under the pediatric exclusivity program.
CONTEXT: In 1997, Congress authorized the US Food and Drug Administration (FDA) to grant 6-month extensions of marketing rights through the Pediatric Exclusivity Program if industry sponsors complete FDA-requested pediatric ...